TG

TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

Retrieved on: 
Friday, November 3, 2023
JW Marriott Hotels, INI, TG, Conference, Therapy, Inflammation, JW Marriott Essex House, Hotel, Online shopping

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference, being held at the JW Marriott Essex House, in New York City on November 6 -7, 2023.

Key Points: 
  • NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference, being held at the JW Marriott Essex House, in New York City on November 6 -7, 2023.
  • The fireside chat is scheduled to take place on Monday, November 6, 2023, at 3:10 PM ET.
  • A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events .

TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Research, European Commission, Medicare, II, SG, Treatment, Multiple sclerosis, Conference, EC, R, D, Centers for Medicare & Medicaid Services, Prescription, Clinical trial, TG, RMS, Finance, Conference call, Therapy, Patient, CMS, Pharmaceutical industry, Health insurance, Cryptocurrency

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2023, along with recent company developments.

Key Points: 
  • Achieved $25.1 million in BRIUMVI net sales for the third quarter 2023; total net product revenue of approximately $48.9 million since launch.
  • Received a permanent J-Code (J2329) for BRIUMVI from the U.S. Centers for Medicare & Medicaid Services (CMS), which became effective July 1, 2023.
  • Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $229.2 million as of September 30, 2023.
  • The Company will host a conference call today, November 1, 2023, at 8:30 AM ET, to discuss the Company’s financial results from the third quarter, ended September 30, 2023.

TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Monday, October 30, 2023
TG, Conference, Therapy, Pharmaceutical industry

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, November 1, 2023, at 8:30 AM ET to discuss results for the third quarter 2023 and provide a business outlook for remainder of the year.

Key Points: 
  • NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, November 1, 2023, at 8:30 AM ET to discuss results for the third quarter 2023 and provide a business outlook for remainder of the year.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, will host the call.
  • In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics.
  • TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Retrieved on: 
Thursday, October 12, 2023
RMS, Treatment, MD, Multiple sclerosis, Therapy, II, Research, TG, Publication, Patient, Pharmaceutical industry

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.

Key Points: 
  • NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.
  • A link to the presentation is included below.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We continue to be impressed by the exploratory analyses of BRIUMVI in multiple sclerosis and look forward to continuing to share additional data from both the ULTIMATE trials as well as ENHANCE.”
    Lead Author: John Foley, MD - Rocky Mountain Multiple Sclerosis, Salt Lake City, UT, USA
    The above presentation is also available within the Publications section of the Company’s website at www.tgtherapeutics.com/publications.cfm.

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Retrieved on: 
Wednesday, October 11, 2023
RMS, MS, Treatment, Maintenance, MD, Multiple sclerosis, Therapy, IV, II, Research, TG, Publication, Patient, Pharmaceutical industry

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.

Key Points: 
  • NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.
  • A link to each presentation is included below.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The exploratory data from the ULTIMATE I & II trials evaluating BRIUMVI in patients with relapsing forms of MS continues to be exciting and highlights the unique attributes of BRIUMVI.
  • Today at the ECTRIMS annual meeting, we were also excited to present the first data from the ENHANCE trial evaluating patients who switch from an IV anti-CD20 antibody to BRIUMVI.”
    ePoster Presentation Title: Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data
    Lead Author: John Foley, MD - Rocky Mountain Multiple Sclerosis, Salt Lake City, UT, USA
    The above referenced presentations are also available within the Publications section of the Company’s website at www.tgtherapeutics.com/publications.cfm.

Bonnell Aluminum Commenting on Recent Trade Filing from Aluminum Extruders Coalition and United Steelworkers Union

Retrieved on: 
Thursday, October 5, 2023
Machine Tools, Metalworking & Metallurgy, Other Construction & Property, Manufacturing, Construction & Property, Other Manufacturing, Steel, United Arab Emirates, U.S. Department of Commerce Office of Security, USW, NYSE, United States International Trade Commission, USITC, United Steelworkers, Aluminium, Dominican Republic, Commerce, Wiley Rein, Growth, TG, U.S. Department of Defense Strategy for Operating in Cyberspace, Tredegar Corporation, Drug

Bonnell Aluminum, a subsidiary of Tredegar Corporation (NYSE: TG), applauds the U.S. Aluminum Extruders Coalition - which Bonnell Aluminum is part of - and the United Steelworkers union following the October 4, 2023, filing of antidumping and countervailing duty petitions to remedy the unfairly traded imports of aluminum extrusions from China, Colombia, the Dominican Republic, Ecuador, India, Indonesia, Italy, Malaysia, Mexico, South Korea, Taiwan, Thailand, Turkey, the United Arab Emirates and Vietnam.

Key Points: 
  • Bonnell Aluminum, a subsidiary of Tredegar Corporation (NYSE: TG), applauds the U.S. Aluminum Extruders Coalition - which Bonnell Aluminum is part of - and the United Steelworkers union following the October 4, 2023, filing of antidumping and countervailing duty petitions to remedy the unfairly traded imports of aluminum extrusions from China, Colombia, the Dominican Republic, Ecuador, India, Indonesia, Italy, Malaysia, Mexico, South Korea, Taiwan, Thailand, Turkey, the United Arab Emirates and Vietnam.
  • “We are determined to end the significant surge of unfairly dumped and subsidized imports of aluminum extrusions that have flooded the U.S. market,” said Brook Hamilton, president of Bonnell Aluminum.
  • “Enforcing our trade laws will ensure that U.S. aluminum manufacturers are given the opportunity to compete on a level playing field.
  • We must stand up for American manufacturers and put an end to the continuous layoffs that are devastating our workers, our industry, and our communities.”

Thermaltake Dedicates Special Gaming Product Deals for Newegg FantasTech Sale II

Retrieved on: 
Monday, October 9, 2023
Partnership, Computer, CTE, TDP, LGA, PC Gamer, TG, ATX, Sale, Video game, Telescopic sight, Thermaltake, Newegg

WALNUT, Calif., Oct. 9, 2023 /PRNewswire-PRWeb/ -- Thermaltake, the leading PC Cases, Cooling, Power, and memory solutions brand, is thrilled to announce its contribution to the Newegg FantasTech Sale II 2023, one of the largest online shopping festivals for PC technophiles. PC Gamers and modders are welcome to enjoy this five-day super sale with unprecedented discounts from October 9 to October 13, 2023, to elevate their desktop PC systems with the selected high-quality Thermaltake gaming products.

Key Points: 
  • We see the FantasTech Sale II 2023 as an excellent opportunity for gamers and technophiles to enjoy our top-selling gaming products at discounted prices."
  • These special deals include their acclaimed CTE gaming PC cases, ToughPower series ATX 3.0 power supplies, and ToughAir/ToughLiquid coolers and fans.
  • We see the FantasTech Sale II 2023 as an excellent opportunity for gamers and technophiles to enjoy our top-selling gaming products at discounted prices."
  • Michael Guo, the Vice President of Thermaltake USA, explained the rationale behind Thermaltake's partnership with Newegg for the FantasTech Sale.

Thermaltake Dedicates Special Gaming Product Deals for Newegg FantasTech Sale II

Retrieved on: 
Monday, October 9, 2023
Partnership, Computer, CTE, TDP, LGA, PC Gamer, TG, ATX, Sale, Video game, Online shopping, Thermaltake, Newegg

WALNUT, Calif., Oct. 9, 2023 /PRNewswire-PRWeb/ -- Thermaltake, the leading PC Cases, Cooling, Power, and memory solutions brand, is thrilled to announce its contribution to the Newegg FantasTech Sale II 2023, one of the largest online shopping festivals for PC technophiles. PC Gamers and modders are welcome to enjoy this five-day super sale with unprecedented discounts from October 9 to October 13, 2023, to elevate their desktop PC systems with the selected high-quality Thermaltake gaming products.

Key Points: 
  • We see the FantasTech Sale II 2023 as an excellent opportunity for gamers and technophiles to enjoy our top-selling gaming products at discounted prices."
  • These special deals include their acclaimed CTE gaming PC cases, ToughPower series ATX 3.0 power supplies, and ToughAir/ToughLiquid coolers and fans.
  • We see the FantasTech Sale II 2023 as an excellent opportunity for gamers and technophiles to enjoy our top-selling gaming products at discounted prices."
  • Michael Guo, the Vice President of Thermaltake USA, explained the rationale behind Thermaltake's partnership with Newegg for the FantasTech Sale.

ApeX Protocol Launches Telegram Bot for Effortless Decentralized Derivatives Trading

Retrieved on: 
Tuesday, October 3, 2023
Hacks, USDC, Bot, Business development, Business, Lead, DEX, Traction, Protocol, Apex, TG, Cryptocurrency, Telegraphy

Saint Vincent and the Grenadines, October 3, 2023 | October 03, 2023 08:11 AM Eastern Daylight Time

Key Points: 
  • Saint Vincent and the Grenadines, October 3, 2023 | October 03, 2023 08:11 AM Eastern Daylight Time
    The leading crypto derivatives DEX, ApeX Protocol , has launched the ApeX Bot , marking a significant milestone as the inaugural L2 DEX Telegram (TG) bot catering to derivatives trading within a decentralized framework.
  • As the first-ever L2 DEX bot supporting derivatives trading, ApeX Bot sets itself apart from the competition, offering various features to users:
    Testnet: Conveniently test platform functions and receive step-by-step guidance.
  • To celebrate the launch of the ApeX Bot, users have the opportunity to earn USDC rewards by referring friends and communities who are new to ApeX Pro using the ApeX Bot.
  • Join ApeX Protocol today and experience the future of decentralized derivatives trading with the ApeX Bot on Telegram.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Retrieved on: 
Monday, October 2, 2023
Abstract (summary), IV, Publication, Multiple sclerosis, TG, II, RMS, Patient, MD, Treatment, Research, Therapy, Maintenance, Pharmaceutical industry, Oil

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy.

Key Points: 
  • NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy.
  • Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: https://apps.congrex.com/ectrims2023/en-GB/pag .
  • The late breaking abstract will be available on October 11, 2023.
  • Details of the presentations are outlined below.